II iSpecimen Inc. Stock: price and directors' dealings · United States · SEC (Form 4)Track the iSpecimen Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, iSpecimen Inc. has logged 24 reports. Market capitalisation: €3.2m. The latest transaction was filed on 15 September 2023 (Acquisition). Among the most active insiders: Ianelli Christopher. The full history is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 15 September 2023
All Executives24 Thresholds0 Prospectus0 Other0
Declarations 24 total
▲ Chief Info Officer & Secretary · Executives · 14 Sept 2023
18,000 shares @ US$0.72 63.4% of flow Common Stock SEC:0001104659-23-101210:0
Canonical exit: 13 Dec 2023 (T+90) ▲ CEO, CFO and Treasurer · Executives · 31 May 2023
4,400 shares @ US$1.25 6.1% of flow Common Stock SEC:0001104659-23-067152:0
Canonical exit: 29 Aug 2023 (T+90) ◆ Director · Executives · 1 Jan 2023
125 shares Common Stock SEC:0001104659-23-061737:0
◆ Director · Executives · 1 Jan 2023
63 shares Common Stock SEC:0001104659-23-061742:0
◆ Director · Executives · 1 Jan 2023
92 shares Common Stock SEC:0001104659-23-061739:0
◆ Director · Executives · 1 Jan 2023
125 shares Common Stock SEC:0001104659-23-061736:0
◆ Director · Executives · 1 Jan 2023
92 shares Common Stock SEC:0001104659-23-061740:0
◆ Director · Executives · 1 Jan 2023
125 shares Common Stock SEC:0001104659-23-061741:0
◇ Director · Executives · 6 Jan 2023
845 shares @ US$1.00 6.5% of flow Common Stock SEC:0001104659-23-005104:0
◇ Director · Executives · 17 Jan 2023
66,637 shares @ US$1.00 71.9% of flow Common Stock SEC:0001104659-23-004999:0
● Director · Executives · 24 Oct 2022
18,229 shares Common Stock SEC:0001104659-22-117765:0
● Director · Executives · 24 Oct 2022
18,229 shares Common Stock SEC:0001104659-22-117133:0
● Chief Information Officer · Executives · 22 Jun 2022
3,148 shares @ US$2.36 0.28% mcap 100.0% of flow Common Stock SEC:0001104659-22-074366:0
● COO and Secretary · Executives · 22 Jun 2022
3,124 shares @ US$2.36 0.27% mcap 29.0% of flow Common Stock SEC:0001104659-22-074370:0
● CEO and President · Executives · 22 Jun 2022
3,903 shares @ US$2.36 0.34% mcap 76.1% of flow Common Stock SEC:0001104659-22-074368:0
● CFO and Treasurer · Executives · 22 Jun 2022
2,738 shares @ US$2.36 0.24% mcap 7.7% of flow Common Stock SEC:0001104659-22-074371:0
◇ President & CEO · Executives · 22 Feb 2022
3,099 shares @ US$1.00 0.11% mcap 23.9% of flow Common Stock SEC:0001104659-22-026697:0
◇ COO & Secretary · Executives · 22 Feb 2022
19,296 shares @ US$1.00 0.67% mcap 71.0% of flow Common Stock SEC:0001104659-22-026191:0
▲ Director · Executives · 17 Jun 2021
100 shares @ US$6.27 0.021% mcap 50.0% of flow Common Stock SEC:0001104659-21-144593:0
Canonical exit: 15 Sept 2021 (T+90) ▲ Chief Financial Officer · Executives · 16 Nov 2021
8,000 shares @ US$5.23 1.45% mcap 46.2% of flow Common Stock SEC:0001104659-21-140720:0
Canonical exit: 14 Feb 2022 (T+90) ● CEO, President · Executives · 21 Jun 2021
2,663 shares Common Stock SEC:0001104659-21-084750:0
● Director · Executives · 21 Jun 2021
355,005 shares Common Stock SEC:0001104659-21-084775:0
250,456 shares Common Stock SEC:0001104659-21-084748:0
● COO, Secretary, Treasurer · Executives · 21 Jun 2021
6,250 shares Common Stock SEC:0001104659-21-084773:0
关于 iSpecimen Inc. iSpecimen Inc.(股票代码:ISPC)是一家在美国纳斯达克资本市场上市的美国生命科学市场公司。其业务处于医疗保健技术和生物医学研究的交汇点。iSpecimen 运营着 iSpecimen Marketplace®,这是一个数字平台,连接生命科学研究人员与人类生物样本提供者,包括医院、生物库、商业实验室、医疗集团、临床试验组织和其他医疗机构。该公司的核心价值主张是简化研究所需人类样本的采购流程,同时帮助提供者组织从未充分利用的库存和临床残余中获取收入。
该公司成立于 2009 年,并于 2012 年完成了首次商业销售。其总部和主要行政办公室位于美国马萨诸塞州沃本,使其处于北美最重要的生物技术集群之一。iSpecimen 的起源故事植根于病理学家发现的一个实际问题:研究人员经常需要手动搜索分散的临床网络以找到合适的样本。这一历史至今仍定义着公司,因为它旨在减少生物样本获取过程中采购、合规、合同签订和物流方面的摩擦。
从业务线角度来看,iSpecimen 专注于几种样本类别,包括生物体液、组织、干细胞和免疫细胞、匹配样本集以及相关的患者数据。该市场旨在为研究人员提供单一界面访问广泛且不断增长的提供者网络,并提供搜索、订购、履行跟踪和数据集访问工具。其客户群主要由研究机构、生物技术公司和制药公司组成,这些公司寻求高度特定的人类样本用于发现项目,特别是在肿瘤学、心血管疾病和其他转化研究领域。
在竞争方面,iSpecimen 将自己定位为一家专业化的、技术驱动的市场,而非传统的经销商。其竞争优势取决于网络广度、数据质量、工作流程效率和合规处理。在一个分散的生物样本市场中,这些因素至关重要:研究人员需要速度和特异性,而提供者则需要标准化流程和可扩展的货币化途径。该模型在理论上具有吸引力,但执行至关重要,因为市场在操作上复杂且受到高度监管。
最近的发展包括持续努力扩大供应商网络和增强市场功能。在财务和股票层面,公司也发生了一些值得关注的事件,包括在 2025 年末进行的私募配售以及在 2026 年 4 月末生效的 1 股拆 40 股反向股票分割,而其普通股继续在纳斯达克以 ISPC 代码交易。对于投资者而言,iSpecimen 仍然是一家小型、成长型医疗保健技术公司,专注于提高市场使用率、深化供应方关系以及改善美国生物样本市场的商业吸引力。